BackgroundCompartment syndrome is an uncommon but life-threatening condition. No study has comprehensively compared compartment syndrome (CS) association with available drugs. The objective of this study was to estimate the association between CS and drugs using the FDA Adverse Event Report System (FAERS).Research design and methodsFAERS reports from the first quarter of 2004 to the third quarter of 2023 were analyzed. The Medical Dictionary for Regulatory Activities (MedDRA) was used to identify CS cases. Reporting odds ratio (ROR), corresponding to 95% confidence intervals (95% CI) were calculated to detect a positive signal.ResultsA total of 2197 reports were considered in the study after the inclusion criteria were applied. Totally 100 drugs were found to be associated with CS. The median time for drug-associated CS was 45 days.ConclusionsBy analyzing the FAERS database, the study revealed that certain drugs are significantly associated with compartment syndrome. Further studies are needed to verify whether these drugs are associated with such a risk.
Kong Wenqiang,Shu Yunfeng,Tang Juan,et al.Compartment syndrome associations with drugs: a pharmacovigilance study of the FDA adverse event reporting system (FAERS)[J].EXPERT OPINION ON DRUG SAFETY.2024,doi:10.1080/14740338.2024.2376687.
APA:
Kong, Wenqiang,Shu, Yunfeng,Tang, Juan,Wan, Jie&Yang, Xueting.(2024).Compartment syndrome associations with drugs: a pharmacovigilance study of the FDA adverse event reporting system (FAERS).EXPERT OPINION ON DRUG SAFETY,,
MLA:
Kong, Wenqiang,et al."Compartment syndrome associations with drugs: a pharmacovigilance study of the FDA adverse event reporting system (FAERS)".EXPERT OPINION ON DRUG SAFETY .(2024)